AUA 2019: ERAS vs. Robotics: Which Provides the Most Incremental Benefit? - Robotics

Chicago, IL (UroToday.com) In a podium debate with Dr. Siamak Daneshmand as part of the Society of Urologic Oncology program at the American Urologic Association Annual Meeting, Dr. Dipen Parekh argued that robotic-assisted radical cystectomy provides greater incremental benefits for patients undergoing radical cystectomy than an enhanced recovery after surgery (ERAS) protocol.

He began by highlighting the complexity of many ERAS protocols which may include between 27 and 34 unique, individual items.

AUA2019_ERAS_protocols.png

Further, according to the ERAS strategy as described by Ljungqvist et al., minimally invasive surgery (such as robotic-assisted radical cystectomy) forms a key component of ERAS approaches.

AUA2019_enhanced_recovery.png

Further, the inclusion of minimally invasive approaches is included in radical cystectomy specific ERAS protocols.

AUA2019_perioperative_care.png

He then quickly highlighted differences in perioperative outcomes from retrospective analyses:

AUA2019_retrospective_analyses.png

Before moving on to evidence derived from randomized controlled trials including Bochner et al., Nix et al., and Parekh et al. In each case, there was a benefit in estimated blood loss, hospital length of stay, and time to bowel recovery to robotic assisted radical cystectomy. He focused on the evidence derived from the RAZOR clinical trial. This multicenter trial demonstrated comparable progression-free survival between open and robotic approaches with decreased blood loss, decreased transfusion rates, and shorter hospital length of stay among patients who received robotic radical cystectomy.

He then went on to highlight the complexity, relatively lower quality of evidence, and lack of demonstrable benefit to ERAS in the published literature.

AUA2019_ERAS_benefit.png
AUA2019_ERAS_benefit2.png


While many ERAS protocols recommend a restrictive fluid strategy, Dr. Parekh highlighted recent evidence that such an approach may increase risks of surgical site infection and acute kidney injury.

AUA2019_fluid_therapy.png

Additionally, while the increased costs of robotic surgery are relatively transparent, Dr. Parekh highlighted the potentially hidden costs of ERAS including pharmacy costs, increased home visits and nursing case, and increased outpatient care visits. These costs may increase as ERAS utilization increases as demonstrated below:

AUA2019_implementation_costs.png



Presented by: Dipen Parekh, MD, Urologic Oncology, University of Miami Health System, Miami, Florida

Written by: Christopher J.D. Wallis, Urology Resident, University of Toronto, Contact: @WallisCJD on Twitter at the American Urological Association's 2019 Annual Meeting (AUA 2019), May 3 – 6, 2019 in Chicago, Illinois

Further Related Content:
ERAS vs. Robotics: Which Provides the Most Incremental Benefit? - ERAS
E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe